In particular, it has taken advantage of a tumor panel comprised of 710 tumor-associated genes to reliably calculate TMB in liquid biopsies deriving from 35 melanoma patients treated with ipilimumab (as anti-CTLA-4) and nivolumab (as anti-PD-1) (27). This evidence concerns the gene PDCD1 and neoplasm.